NCT06916546Completed
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
Yttrium-90 Selective Internal Radiation Therapy (SIRT) Combined With Lenvatinib and PD-(L)1 Inhibitors Versus Transarterial Chemoembolization (TACE) Combined With Lenvatinib and PD-(L)1 Inhibitors for Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
Source: ClinicalTrials.gov · Last updated 8 Apr 2025
Brief summary (registry, in English)
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitors (TACE-L-P) in patients with HCC beyond up-to-seven criteria or with portal vein tumor thrombus (PVTT). Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the two groups.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 238 (actual)
- First submitted
- 31 Mar 2025
- Start date
- 1 Jun 2022
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06916546
What you commit to
- Study type: Observational
- Participants enrolled: 238
- From 1 Jun 2022 to the primary completion date, 31 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receipt of other loco-regional therapies, including hepatic arterial infusion chemotherapy, external radiation therapy, or radioactive seed implantation
- Prior systemic therapy
Other illness
- History of other malignancies
Other
- incomplete medical records
Who the study is looking for
- histologically or clinically confirmed diagnosis of HCC at BCLC stage B or C (extrahepatic metastases were allowed)
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- Child-Pugh class A or B7
- unresectable HCC with intrahepatic tumor beyond up-to-seven criteria and/or with PVTT.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The second Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.